Stoke Therapeutics (NASDAQ:STOK) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK) in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a $47.00 price objective on the stock.

Several other analysts have also recently issued reports on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Chardan Capital reissued a “buy” rating and set a $24.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Tuesday. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $23.00.

Stoke Therapeutics Stock Performance

Shares of NASDAQ STOK opened at $8.26 on Wednesday. Stoke Therapeutics has a fifty-two week low of $5.60 and a fifty-two week high of $17.58. The stock has a market cap of $437.51 million, a PE ratio of -3.93 and a beta of 0.99. The stock has a fifty day moving average of $9.50 and a 200-day moving average of $11.51.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The business had revenue of $22.61 million during the quarter, compared to analyst estimates of $4.20 million. On average, sell-side analysts predict that Stoke Therapeutics will post -2.01 EPS for the current year.

Institutional Trading of Stoke Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of STOK. Bank of New York Mellon Corp lifted its holdings in shares of Stoke Therapeutics by 1.4% in the 4th quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company’s stock worth $1,028,000 after acquiring an additional 1,330 shares during the last quarter. Graham Capital Management L.P. lifted its stake in Stoke Therapeutics by 8.5% in the fourth quarter. Graham Capital Management L.P. now owns 18,634 shares of the company’s stock worth $206,000 after purchasing an additional 1,453 shares during the last quarter. Gilder Gagnon Howe & Co. LLC boosted its position in Stoke Therapeutics by 2.0% during the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 92,546 shares of the company’s stock valued at $1,021,000 after buying an additional 1,791 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Stoke Therapeutics by 6.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 37,455 shares of the company’s stock valued at $414,000 after buying an additional 2,215 shares during the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of Stoke Therapeutics by 6.0% in the fourth quarter. Rhumbline Advisers now owns 49,374 shares of the company’s stock worth $545,000 after buying an additional 2,787 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.